<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386266</url>
  </required_header>
  <id_info>
    <org_study_id>05171</org_study_id>
    <nct_id>NCT03386266</nct_id>
  </id_info>
  <brief_title>Biomarkers and Validation of Selected Outcome Measures (CMTNSmod)</brief_title>
  <official_title>Biomarkers and Validation of Selected Outcome Measures (CMTNSmod)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Goettingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CMT is a rare disease for which novel treatments are being developed. Evaluation of
      intervention efficacy is hampered by slow progression and lack of sensitive outcome measures.
      Primary goal of the project is to identify and validate RNA and protein derived biomarkers in
      blood of CMT patients for selected outcome measures over 2 years. The investigators expect to
      develop more responsive outcome measures and circulating biomarkers to improve assessment of
      intervention efficacy in forthcoming therapeutic trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Novel treatments are being developed for CMT. Intervention efficacy evaluation is hampered by
      slow disease progression and lack of sensitive outcome measures. The investigators have
      previously shown that biomarkers from skin identified in a CMT1A rat model can be translated
      to CMT1A patients. Primary goal is to identify circulating biomarkers correlating with
      disease severity and progression. 210 young, adolescent and adult patients affected by
      genetically confirmed CMT1A, will be evaluated with different clinical outcome measures,
      assessing impairment, disability and quality of life: Patients will be re-evaluated at 12
      (n=147) and 24 months (n=103) with the same measures to assess disease progression. A number
      of candidate markers correlating with disease severity have been identified in blood samples
      from the rat model of CMT1A. At 0-12-24 months a blood sample will be drawn from affected
      CMT1A patients. The investigators will purify total mRNA from blood samples, and validate the
      10 strongest regulated markers identified in the rat model via qRTPCR in blood of CMT1A
      patients. Protein biomarkers will also be analysed. Marker expression at baseline and at
      follow up will be correlated with clinical severity and progression. In this translational
      project (rat/human) the investogators expect to develop more responsive outcome measures and
      circulating biomarkers to improve assessment of intervention efficacy in forthcoming
      therapeutic trials.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 11, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mRNA Expression Levels in blood samples from CMT1A patients</measure>
    <time_frame>3 years</time_frame>
    <description>Validation of key candidate genes (GSST2, FN3KRP, CTSA, SPRR1A) fro former studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mRNA Expression Levels in Skin biopsies from CMT1A patients</measure>
    <time_frame>3 years</time_frame>
    <description>Validation of key candidate genes (GSST2, FN3KRP, CTSA, SPRR1A) fro former studies</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Charcot-Marie-Tooth Disease, Type IA</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA and RNA from blood and skin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from CMT1A disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of CMT1A

          -  Genetic confirmation of PMP22 duplication (for adults patients)

          -  Children aged 3-11, adolescents aged 12-17 and adults aged 18-65 years

          -  Signed informed patient consent

        Exclusion Criteria:

          -  Other causes of neurological and psychiatric disorders

          -  Severe internistic disease

          -  Patient known or suspected to be alcohol / drug abuser

          -  Pregnancy, breast feeding period

          -  Permanent Vitamin C intake

          -  Participation an interventional clinical study up to 4 weeks prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W. Sereda, MD, Professor of Neurology</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Goettingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Goettigen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mannil M, Solari A, Leha A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B, Walter MC, Rautenstrauss B, Schnizer TJ, Schenone A, Seeman P, Kadian C, Schreiber O, Angarita NG, Fabrizi GM, Gemignani F, Padua L, Santoro L, Quattrone A, Vita G, Calabrese D; CMT-TRIAAL/CMT-TRAUK Group, Young P, Laurà M, Haberlová J, Mazanec R, Paulus W, Beissbarth T, Shy ME, Reilly MM, Pareyson D, Sereda MW. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscul Disord. 2014 Nov;24(11):1003-17. doi: 10.1016/j.nmd.2014.06.431. Epub 2014 Jun 19.</citation>
    <PMID>25085517</PMID>
  </reference>
  <reference>
    <citation>Fledrich R, Schlotter-Weigel B, Schnizer TJ, Wichert SP, Stassart RM, Meyer zu Hörste G, Klink A, Weiss BG, Haag U, Walter MC, Rautenstrauss B, Paulus W, Rossner MJ, Sereda MW. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. Brain. 2012 Jan;135(Pt 1):72-87. doi: 10.1093/brain/awr322. Epub 2011 Dec 20.</citation>
    <PMID>22189569</PMID>
  </reference>
  <results_reference>
    <citation>Fledrich R, Mannil M, Leha A, Ehbrecht C, Solari A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B, Schnizer TJ, Prukop T, Garcia-Angarita N, Czesnik D, Haberlová J, Mazanec R, Paulus W, Beissbarth T, Walter MC, Triaal C, Hogrel JY, Dubourg O, Schenone A, Baets J, De Jonghe P, Shy ME, Horvath R, Pareyson D, Seeman P, Young P, Sereda MW. Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):941-952. doi: 10.1136/jnnp-2017-315721. Epub 2017 Aug 31.</citation>
    <PMID>28860329</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Goettingen</investigator_affiliation>
    <investigator_full_name>Michael W Sereda, MD, Professor of Neurology</investigator_full_name>
    <investigator_title>Michael W Sereda, MD, Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>CMT1A</keyword>
  <keyword>Charcot-Marie-Tooth disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

